CHESHIRE, UK--(Marketwire - September 02, 2008) - London, UK; Brentwood, TN; 2 September 2008 - In conformity with the Transparency Directive, Protherics PLC (“Protherics”), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
